Table 2. Minimal residual viremia according to treatment regimen.
| Treatment regimen | Median treatment duration(months) | Analyzed serumsamples(n) | Serum samples with minimalresidual viremia (%) |
| Lamivudine monotherapy | 23 (5–84) | 54 | 50% |
| Adefovir monotherapy | 42 (11–76) | 41 | 54% |
| Telbivudine monotherapy | 19 | 6 | 83% |
| Entecavir monotherapy | 33.5 (27–40) | 21 | 95% |
| Tenofovir monotherapy | 14 (9–19) | 10 | 70% |
| Lamivudine+Adefovir | 22 (3–37) | 25 | 56% |
| Lamivudine/Emtricitabine+Tenofovir | 27.5 (9–41) | 42 | 81% |
| Tenofovir+Entecavir | 15 (3–28) | 17 | 65% |